A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in patients (pts) with colorectal cancer (CRC) refractory to standard regimens

MLA

Federico Caligaris-Cappio, et al. “A Phase II Study of NGR-HTNF, a Novel Vascular Targeting Agent (VTA), Administered as Single Agent at Low Dose in Patients (Pts) with Colorectal Cancer (CRC) Refractory to Standard Regimens.” Journal of Clinical Oncology, vol. 26, May 2008, p. 4110. EBSCOhost, https://doi.org/10.1200/jco.2008.26.15_suppl.4110.

APA

Federico Caligaris-Cappio, E. Bennicelli, Antonella Santoro, Vanesa Gregorc, Antonio Lambiase, Francesco Sclafani, Lorenza Rimassa, Claudio Bordignon, F. Caprioni, & Valeria Andretta. (2008). A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in patients (pts) with colorectal cancer (CRC) refractory to standard regimens. Journal of Clinical Oncology, 26, 4110. https://doi.org/10.1200/jco.2008.26.15_suppl.4110

Chicago

Federico Caligaris-Cappio, E. Bennicelli, Antonella Santoro, Vanesa Gregorc, Antonio Lambiase, Francesco Sclafani, Lorenza Rimassa, Claudio Bordignon, F. Caprioni, and Valeria Andretta. 2008. “A Phase II Study of NGR-HTNF, a Novel Vascular Targeting Agent (VTA), Administered as Single Agent at Low Dose in Patients (Pts) with Colorectal Cancer (CRC) Refractory to Standard Regimens.” Journal of Clinical Oncology 26 (May): 4110. doi:10.1200/jco.2008.26.15_suppl.4110.